Status
Acquired by Actelion Pharmaceuticals on July 31, 2013
Funding Received
$25 Million in 2 Rounds from 8 Investors
Headquarters:
Malvern, PA
Description:
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
Categories:
Biotechnology
Website:
http://www.ceptaris.com

Company Details

Update
Founded:
2002
Employees:
11 in CrunchBase

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Current Team (11)

Update

Board Members and Advisors (4)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    101 Lindenwood Drive

    Suite 400

    Malvern, PA 19355

    USA

Images (1)

Update
  • 8243f38eb635c477bc27463f1c1b2575